Journal of Affective Disorders
April 1, 2018
Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak et al.
57 citations
Background: Natural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here, we used a machine learning algorithm applied to natural speech to ask whether language properties measured before psilocybin for treatment-resistant can predict for which patients it will be effective and for which it will...
Medical Hypotheses
March 23, 2018
K.p.c. Kuypers
16 citations
Our creativity is challenged daily when facing new situations asking for novel solutions. Creativity, a multicomponent construct includes flexible divergent and rigid convergent thinking. Psychedelic drugs like psilocybin can enhance creativity and affect state of mind (mood, empathy, openness). Of note, flexible thinking is disturbed in psychopathological conditions like anxiety disorders and...
Behavioural Pharmacology
March 13, 2018
Rachel R. Horsley, Tomáš Páleníček, Jan Kolin et al.
52 citations
Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent 'microdosing' (usually one-tenth of a 'full' active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to...
Neurocase
March 4, 2018
Vilayanur S. Ramachandran, Chaipat Chunharas, Zeve Marcus et al.
63 citations
AL's leg was amputated resulting in phantom-limb pain (PLP). (1) When a volunteer placed her foot on or near the phantom - touching it evoked organized sensations in corresponding locations on AL's phantom. (2) Mirror-visual-feedback (MVF) relieved PLP, as did, "phantom massage". (3) Psilocybin-MVF pairing produced synergistic effects, complete elimination of PLP, and reduction in paroxysmal...
SHILAP Revista de lepidopterología
March 1, 2018
Elaheh Mahmoudi, Mehrdad Faizi, Reza Hajiaghaee et al.
14 citations
Background and objectives: Considering the increasing prevalence of depression, many studies are launched to investigate new antidepressant treatments. The present research has shown how psilocybin as an active compound of Psilocybe cubensis (Earle) Singer extract (PCE) can change the parameters related to depression and anxiety in animal models. Both serotonin (5-hydroxytryptamine: 5-HT) and...
Evolution Letters
February 27, 2018
Hannah T. Reynolds, Vinod Vijayakumar, Emile Gluck‐thaler et al.
114 citations
Abstract Secondary metabolites are a heterogeneous class of chemicals that often mediate interactions between species. The tryptophan-derived secondary metabolite, psilocin, is a serotonin receptor agonist that induces altered states of consciousness. A phylogenetically disjunct group of mushroom-forming fungi in the Agaricales produce the psilocin prodrug, psilocybin. Spotty phylogenetic...
Frontiers in Pharmacology
February 21, 2018
Elizabeth M. Nielson, Darrick G. May, Alyssa A. Forcehimes et al.
111 citations
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence. Detailed description of the content and methods of psychedelic-assisted psychotherapy, as it is conducted in clinical settings, is scarce. Methods: An open-label pilot (proof-of-concept) study of psilocybin-assisted treatment of alcohol...
Frontiers in Pharmacology
February 20, 2018
Michael P. Bogenschutz, Samantha K. Podrebarac, Jessie H. Duane et al.
125 citations
After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete,...
ACS Chemical Neuroscience
February 20, 2018
David E. Nichols
87 citations
Lysergic acid diethylamide (LSD) is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 μg) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
February 2, 2018
Simon Reiche, Leo Hermle, Stefan Gutwinski et al.
125 citations
Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently,...
Psychopharmacology
February 1, 2018
Theresa M. Carbonaro, Matthew W Johnson, Ethan Hurwitz et al.
139 citations
Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and...
Jurnal Kimia
January 30, 2018
N. M. Uaniti, O. O. Ratnayani, S. A. Sari
1 citation
Penelitian ini bertujuan mekstraksi senyawa halusinogen dalam magic mushroom yang dilakukan dengan metode SPE (Solid Phase Extraction) menggunakan pelarut methanol dilanjutkan dengan penentuan kandungan senyawanya dengan kromatografi gas-spektrofotometer massa (GC-MS). Hasil analisis dengan GC-MS menghasilkan dua puncak spektrum dengan spektrum dominan yang diidentifikasi sebagai senyawa...
Frontiers in Neuroscience
January 22, 2018
Camila Sanz, Federico Zamberlán, Earth Erowid et al.
112 citations
Ever since the modern rediscovery of psychedelic substances by Western society, several authors have independently proposed that their effects bear a high resemblance to the dreams and dreamlike experiences occurring naturally during the sleep-wake cycle. Recent studies in humans have provided neurophysiological evidence supporting this hypothesis. However, a rigorous comparative analysis of...
Journal of Palliative Medicine
January 22, 2018
Ira Byock
164 citations
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent...
Journal of Psychopharmacology
January 17, 2018
Taylor Lyons, Robin Carhart-Harris
176 citations
Rationale: Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim: Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian–authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods:...
Frontiers in Pharmacology
January 17, 2018
Leor Roseman, David Nutt, Robin Carhart-Harris
814 citations
Introduction: It is a basic principle of the "psychedelic" treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic...
Psychopharmacology
January 5, 2018
Anna Bravermanová, Michaela Viktorinová, Filip Tylš et al.
50 citations
RationaleDisruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of psychosis, but the role of serotonergic 5-HT2A receptors in information processing is less...
Current Topics in Behavioral Neurosciences
2018
Michael Kometer, Franz X. Vollenweider
Serotonergic hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), are famous for their capacity to temporally and profoundly alter an individual's visual experiences. These visual alterations show consistent attributes despite large inter- and intra-individual variances. Many reports document a common perception of colors as more saturated, with...
Progress in Brain Research
2018
Danilo de Gregorio, Justine P. Enns, Nicolas A. Nunez et al.
95 citations
Depression and anxiety are psychiatric diagnoses commonly associated with low quality of life and low percentage of responsiveness by patients treated with currently available drugs. Thus, research into alternative compounds to treat these disorders is essential to guarantee a patient's remission. The last decade has witnessed a revamped interest for the application of psychedelic medicine for...
Progress in Brain Research
2018
Felix Müller, Matthias E. Liechti, Undine E. Lang et al.
32 citations
The effects of hallucinogenic drugs on the human brain have been studied since the earliest days of neuroimaging in the 1990s. However, approaches are often hard to compare and results are heterogeneous. In this chapter, we summarize studies investigating the effects of hallucinogens on the resting brain, with a special emphasis on replicability and limitations. In previous studies,...